Clinical Trial Update: Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2 and Phase 3 trial updates on sublingual immunotherapy for house dust mite–related allergic rhinitis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Sublingual immunotherapy for house dust mite allergy (Sublingual immunotherapy)

Snippet

Sponsor: Stallergenes Greer | Conditions: Allergic Rhinitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-05-19